PHAXIAM Therapeutics S.A. (0QSS.L) LSE
0.10
+0.0065(+6.91%)
Currency In EUR
- General
- Statistics
- Historical Data
- Profile
- Financials
PHAXIAM Therapeutics S.A.
Sector
Healthcare
Industry
Biotechnology
Employees
68
First IPO Date
September 19, 2014
Key Executives
| Name | Title | Pay | Year Born |
| Jérôme Bailly | Deputy Chief Executive Officer, Deputy GM, Chief Quality Officer & Qualified Person | 257,789 | 1979 |
| Thibaut du Fayet | Chief Executive Officer | 355,471 | 1968 |
| Bridget Bax | Consultant & Member of Scientific Board | 0 | N/A |
| Philip L. Lorenzi | Consultant & Member of Scientific Board | 0 | N/A |
| Arthur E. Frankel | Consultant & Member of Scientific Board | 0 | N/A |
| Eric Raymond | Consultant & Member of Scientific Board | 0 | N/A |
| Pascal Birman | Chief Medical Officer | 0 | N/A |
| Frédéric Mathat | Chief Financial Officer | 0 | N/A |
| Cindy Fevre | Chief Scientific Officer | 0 | N/A |
| Naomi Eichenbaum | Director Investor Relations | 0 | N/A |
Description
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.
